Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
By D. Black, A. Schwartz, K. Ensrud, J. Cauley, S. Levis, S. Quandt, S. Satterfield, R. Wallace, D. Bauer, L. Palermo and 4 more. Journal of the American Medical Association (JAMA), 2006
1,433 citations recorded by the source corpus.
Subfields: Oncology, Orthopedics and Sports Medicine
View Paper: https://www.semanticscholar.org/paper/5ac286d77f9af1ae2f0a27a69412c1b03be79ac6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Orthopedics and Sports Medicine
Citations in the corpus
- The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Denosumab has been associated with very rare cases of AFF and ONJ.”
- Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014, background): “There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research (2010, background): “Based on studies with alendronate((162)) and risedronate,((163,164)) patients with osteoporosis will have an antifracture benefit for at least 5 years.”
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, background): “The authors conclude that the risk of nonvertebral fractures and radiographic vertebral fractures did not increase over 5 years after alendronate was discontinued; however, the risk of clinical vertebral fractures was reduced by 55% in patients who remained on treatment for 10 years [160].”
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary (2010, background): “Rates of clinical vertebral fracture decreased by 55% among those who continued alendronate therapy after five years of initial treatment (for a total of 10 years) relative to those who stopped after five years, but there were no differences in rates of nonvertebral fractures or radiographic vertebr”
- The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) (2011, result): “those with existing vertebral fractures or very low BMD after initial alendronate treatment were at highest risk of new fractures and may most benefit by continuing.((8,28)) Future analyses in our study will examine in detail factors that might aid clinical decision making regarding continuation: pr”